Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs
CNBC Stocks· Aug 4, 2026 · 11:38 AM
Pfizer said it cut its full-year revenue expectation for its Covid products to $4 billion, down from around $5 billion previously.
This is a summary. Read the complete story at CNBC Stocks below.
Read full article at CNBC StocksRelated Stories
stocksabout 7 hours ago
Exclusive-Anthropic considers releasing new AI model ahead of IPO, sources say
Investing.com
stocksabout 7 hours ago
Morgan Stanley private credit fund redemption requests remain elevated in third quarter
Investing.com
stocksabout 7 hours ago
Gemini hacked three companies in first known breakout by Google’s AI
Investing.com